Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 05, 2007. The report serves to disclose specific corporate governance updates in accordance with the Financial Services Authority's Listing Rules.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding board appointments and contains no financial performance data.
Material Changes
The primary material change disclosed is the appointment of Professor Sir Roy Anderson to the Board of GlaxoSmithKline plc, effective October 1, 2007.
Management Commentary and Risks
- Board Appointment: Professor Anderson has not served as a director of a publicly quoted company in the past five years.
- Shareholdings: Professor Anderson does not hold, nor have any interests in, any GlaxoSmithKline plc Ordinary shares or American Depositary Shares.
- Regulatory Disclosures: There are no details to disclose regarding LR 9.6.13R (2) to (6) of the Financial Services Authority's Listing Rules.
Investor Verification Checklist
- Verify the effective date of Professor Anderson's board appointment (October 1, 2007).
- Confirm the absence of shareholdings or interests in the company by the new director.
- Note that this filing does not contain financial results; refer to Form 20-F for financial data.